Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 4, 2017

Primary Completion Date

January 24, 2018

Study Completion Date

January 24, 2018

Conditions
UveitisUveitis, PosteriorUveitis, AnteriorUveitis, IntermediatePanuveitis
Interventions
DRUG

4 mg CLS-TA Suprachoriodal Injection

CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints

Trial Locations (10)

23502

Virginia Eye Consultants, Norfolk

30060

Marietta Eye Clinic, Marietta

33308

Retina Group of Florida, Fort Lauderdale

46290

Midwest Eye Retina Practicing at Midwest Eye Institute, Indianapolis

75231

Texas Retina Associates, Dallas

77030

Retina Consultants of Houston, Houston

85014

Retinal Consultants of Arizona, Phoenix

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

94040

Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Clearside Biomedical, Inc.

INDUSTRY